Terns Pharmaceuticals Inc expected to post a loss of 34 cents a share - Earnings Preview

Terns Pharmaceuticals

02/08/2024 14:59

* Terns Pharmaceuticals Inc  TERN.OQ   TERN.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 6 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Terns Pharmaceuticals
Inc is
for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Terns
Pharmaceuticals Inc is $15.00​, above​ its last closing price
of $7.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.34       -0.34      -0.30     Beat    11.1
 Jan. 1 0001               -0.29      -0.29     Met     0.8
 Sep. 30 2023              -0.31      -0.42     Missed  -37.5​
 Jun. 30 2023              -0.34      -0.25     Beat    26.2
 ​​Mar.                    -0.27      -0.31     Missed  
 31 2023                                                
 Dec. 31 2022  -0.39       -0.43      -0.29     Beat    32.6​
 Jan. 1 0001   -0.47       -0.52      -0.44     Beat    
 Jan. 1 0001   -0.56       -0.59      -0.55     Beat    7.3
 This summary was machine generated August 2 at 13:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)